在肺动脉高血压患者中,resistin可以预测疾病的严重程度和生存率
Li Gao1, John Skinner2, Tanmay Nath3
1Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Room 3B.65B, Baltimore, MD, 21224-6821, USA. lgao2@jhmi.edu.
Respiratory research
|June 6, 2024
概括
肺动脉高血压 (PAH) 患者的抵抗水平升高表明疾病严重程度和死亡风险增加. 这种细胞因子显示出作为PAH预后的新生物标志物的潜力,并可能指导新的治疗策略.
科学领域:
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
- 生物标志物发现发现
背景情况:
- 肺动脉高血压 (PAH) 涉及肺动脉异常重塑,导致抵抗力增加,右心室缩和衰竭.
- 尽管治疗进展,但PAH的预后仍然很差,需要新的生物标志物来评估疾病和预测存活率.
- 细胞因子抵抗在PAH病理生物学中的作用需要作为潜在的遗传和生物标记物进行调查.
研究的目的:
- 为了评估血清抵抗素水平作为疾病严重程度的生物标志物在大量的PAH患者队列.
- 评估PAH中抗原水平,临床变量和遗传因素之间的关联.
- 用多变量回归和机器学习来确定PAH生存预测中抵抗因子的预后值.
主要方法:
- 对1121名成年PAH患者 (IPAH和SSc-PAH) 的生物样本,临床和遗传数据的分析.
- 使用ELISA测量血清抵抗素水平,并检查与临床和遗传数据的关联.
- 机器学习算法的应用,以开发和比较死亡风险预测模型.
主要成果:
- 与对照组相比,PAH患者 (包括IPAH和SSc-PAH亚型) 的血清抵抗水平显著更高.
- 高抗原水平与年龄较大,步行距离减少6分钟,以及PAH患者心脏表现较差相关.
- 升高的抗原水平与PAH患者的死亡风险增加有关 (HR: 2.6).
结论:
- 耐药素在人类PAH的病理生物学中发挥着重要作用,并作为预后的新生物标志物.
- 血清抵抗水平可能表明PAH的新治疗标.
- 机器学习模型结合了抵抗剂水平,证明了PAH存活率的预后值有所改善.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Vascular Resistance
3.8K
Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
3.8K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
77
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
77


